Name | SAR405838 |
Synonyms | MI 77301 SAR405838 SAR 405838 SAR-405838 MI-773 (SAR405838) SAR405838 (MI-773) SAR405838, MI-77301 MI-77301 (SAR405838) (2'S,3R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-1,2-dihydro-N-(trans-4-hydroxycyclohexyl)-2-oxo-spiro[3H-indole-3,3'-pyrrolidine]-5'-carboxamide |
CAS | 1303607-60-4 |
Molecular Formula | C29H34Cl2FN3O3 |
Molar Mass | 562.5 |
Density | 1.36±0.1 g/cm3(Predicted) |
Boling Point | 732.1±60.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
pKa | 12.03±0.70(Predicted) |
Storage Condition | -20℃ |
In vitro study | MI-773 can bind to MDM2 with a Ki of 0.88 nm. MI-773 effectively inhibited the proliferation of SJSA-1, RS4;11, LNCaP, and HCT-116 tumor cells, with IC50 values of 0.092 μm, 0.089 μm, 0.27 μm, and 0.20 μm, respectively. MI-773 showed high selectivity for p53 mutant or knockout tumor cell lines, including SAOS-2, PC-3, SW620 and HCT-116(p53-/-) cell lines, with IC50 values greater than 10 μm, 10 M, 10 M and 20 M. MI-773 can bind to MDM2 with a Ki of 0.88 nm. MI-773 effectively inhibited the proliferation of SJSA-1, RS4;11, LNCaP, and HCT-116 tumor cells, with IC50 values of 0.092 μm, 0.089 μm, 0.27 μm, and 0.20 μm, respectively. MI-773 showed high selectivity for tumor cell lines with p53 mutation or knockout, including SAOS-2, PC-3, SW620 and HCT-116(p53 |
In vivo study | In SJSA 1 osteosarcoma, RS4;11 acute lymphoblastic leukemia, LNCaP prostate cancer, and HCT-116 colon cancer xenograft models, MI-773(10, 30, 50, 100, and 200mg/kg,p.o.) can effectively inhibit tumor growth, the inhibitory effect is dose dependent. In SJSA 1 osteosarcoma, RS4;11 acute lymphoblastic leukemia, LNCaP prostate cancer and HCT-116 colon cancer xenograft models, MI-773(10, 30, 50, 100 and 200mg/kg,p.o.) can effectively inhibit tumor growth, the inhibitory effect is dose dependent. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.778 ml | 8.889 ml | 17.778 ml |
5 mM | 0.356 ml | 1.778 ml | 3.556 ml |
10 mM | 0.178 ml | 0.889 ml | 1.778 ml |
5 mM | 0.036 ml | 0.178 ml | 0.356 ml |
biological activity | MI-773 (SAR405838) is an oral bioeffective MDM2 antagonist with Ki of 0.88 nM. Phase 1. MI-773 (SAR405838) is an oral bioeffective MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
In vitro study | MI-773 can be combined with MDM2 with a Ki value of 0.88 nm. MI-773 can effectively inhibit SJSA-1 and RS4;11. The IC50 values of LNCaP and HCT-116 tumor cells are 0.092 μM, 0.089 μM, 0.27 μM and 0.20 μM respectively. MI-773 showed high selectivity to tumor cell lines with p53 mutation or knockout, including SAOS-2, PC-3, SW620 and HCT-116(p53-/-) cell lines, with IC50 values greater than 10 μM, 10 μM, 10 μM and 20 μM respectively. MI-773 can be combined with MDM2, and its Ki value is 0.88 nm. MI-773 can effectively inhibit SJSA-1 and RS4;11. The IC50 values of LNCaP and HCT-116 tumor cells are 0.092 μM, 0.089 μM, 0.27 μM and 0.20 μM respectively. MI-773 showed high selectivity to p53 mutation or knockout tumor cell lines, including SAOS-2, PC-3, SW620 and HCT-116(p53 |
in vivo study | in SJSA 1 osteosarcoma, RS4; In 11 acute lymphoblastic leukemia, LNCaP prostate cancer and HCT-116 colon cancer transplanted tumor models, MI-773(10, 30, 50, 100 and 200 mg/kg,p.o.) can effectively inhibit tumor growth, and the inhibitory effect is dose-dependent. in SJSA 1 osteosarcoma, RS4;11 acute lymphoblastic leukemia, LNCaP prostate cancer and HCT-116 colon cancer transplanted tumor models, MI-773(10, 30, 50, 100 and 200 mg/kg,p.o.) can effectively inhibit tumor growth, and its inhibitory effect is dose-dependent. |
target | TargetValue p53 MDM2 (Cell-free say) 0.88 nM(Ki) |
Target | Value |
p53 | |
MDM2 (Cell-free assay) | 0.88 nM(Ki) |